Multiomics profiling of extracorporeal cross-circulation with gene-edited pig liver xenografts in four human decedents provides comprehensive information on immune, coagulation and metabolic parameters that will help in the clinical development of this strategy for delivering hepatic support to patients with liver failure.

COMPASS is a pan-cancer foundation model that predicts immunotherapy response, across cancer types and treatments, from bulk tumor transcriptomes.

In an open-label randomized trial, a polypill containing three types of heart failure medication (metoprolol, spironolactone and empagliflozin) improved left ventricular ejection fraction and resulted in a smaller number of heart failure hospitalizations or emergency room visits at 6 months, as compared to enhanced usual care.

The authors present a framework for the selection of immune aging biomarkers suitable for clinical trials in geroscience, alongside a translational roadmap for biomarker development to support the next generation of clinical studies on immune aging.

In a phase 1 trial, treatment with the antibody−drug conjugate DYP688, targeting PMEL and delivering a G_q/11 inhibitor, in patients with GNAQ/GNA11-mutant metastatic uveal melanoma or other GNAQ/GNA11-mutant melanomas, showed acceptable safety and encouraging preliminary efficacy, with supporting biomarker data for proof of mechanism.

In a non-randomized phase 1 trial, patients with recurrent glioblastoma received anti-LAG-3 relatlimab with or without anti-PD-1 nivolumab, showing that both monotherapy and combination therapy are safe and result in encouraging preliminary clinical response signals.

NeuroVFM, trained on routine health system MRI and CT scans, learns general neuroimaging representations that improve diagnosis, report generation and triage, showing how private clinical data will power safer, more accurate medical AI.

In phase 1b/2 trial, the treatment of patients with metastatic KRAS^G12D-mutant pancreatic cancer, the intravenously delivered KRAS-G12D inhibitor HRS-4642 plus nab-paclitaxel and gemcitabine led to encouraging clinical response rates that support investigation in larger trials.

A phase 1/2 trial of an off-the-shelf stem cell-derived dopaminergic progenitor therapy demonstrated a favorable 12-month safety profile, with no graft-related adverse events, dyskinesias or tumor formation, although risks were associated with the immunosuppression regimen.

Benchmark estimates from 2017–2021 provide an updated assessment of progress toward the WHO Global Breast Cancer Initiative survival targets across all 194 Member States.

The 2024 revision of the McDonald diagnostic criteria is an important step toward earlier and more inclusive diagnosis of multiple sclerosis. Realizing its full potential will require continued refinement of biomarkers, disease stratification and clinical trial approaches.

Once confined to post-market surveillance, real-world evidence is now being used to emulate trials, guide approvals and even run studies in real time, forcing a rethink of what constitutes a clinical trial.

As a new generation of cancer drugs continues to extend the lives of people with cancer, strategies for recording and managing their toxicity and long-term effects will need innovation too.

Two studies show that agentic artificial intelligence (AI) models could aid decision-making at various stages of patient management, including diagnosis, treatment and hospital admission, but neither model is ready yet for real-world clinical use.

A new study examines the impact of the national HPV vaccination program in England, initiated almost two decades ago — showing huge declines in cervical cancer mortality among young women.